Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. May 15, 2019; 11(5): 436-448
Published online May 15, 2019. doi: 10.4251/wjgo.v11.i5.436
Table 2 Comparison of contrast-enhanced ultrasound characteristics between hepatic neuroendocrine neoplasm group and hepatocellular carcinoma group, n (%)
Contrast-enhanced Ultrasound characteristicshNEN group, n = 55HCC group, n = 55t/χ2P value
Initial enhancement time in s16.23 ± 5.2916.52 ± 5.170.2910.772
Washout to iso-enhancement time in s26.91 ± 15.3947.26 ± 16.846.6150.000
Washout to hypo-enhancement time in s59.84 ± 37.9199.63 ± 61.825.0920.000
Enhancement level at arterial phaseHigh53 (96.4)55 (100)2.0370.154
Equal2 (3.6)0 (0)
Low0 (0)0 (0)
Enhancement level at portal venous phaseEqual7 (12.7)11 (20.0)1.0630.303
Low48 (87.3)44 (80.0)
Enhancement level at late phaseEqual2 (3.6)1 (1.8)0.3430.558
Low53 (96.4)54 (98.2)
Enhancement formsFast forward and fast out53 (96.4)51 (92.8)0.7050.401
Equal/slow forward and fast out2 (3.6)4 (7.2)
Enhancement formsUniform33 (60)39 (70.9)1.4470.229
Non-uniform22 (40)16 (29.1)
Tumor vasculatureYes34 (61.8)38 (69.1)0.6430.423
No21 (38.2)17 (30.9)
Tumor necrosisYes16 (29.1)19 (34.5)0.3770.539
No39 (70.9)36 (65.5)
Capsule enhancementYes7 (12.7)2 (3.6)3.0250.082
No48 (87.3)53 (96.4)